The report provides comprehensive insights about an investigational product for Duchenne Muscular Dystrophy in 7 Major Markets.
A detailed picture of the Inclisiran in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.
The product details cover mechanism of action, dosage and administration, route of synthesis, and research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Inclisiran, an investigational cholesterol-lowering treatment, was added to the pipeline from the Novartis acquisition of The Medicines Company. Inclisiran will potentially be the first and only LDL-C lowering siRNA treatment. It is intended to be administered by a healthcare professional by subcutaneous injection with an initial dose, again at 3 months and then every 6 months thereafter.
Alnylam Pharmaceuticals discovered inclisiran and licensed it to The Medicines Company in 2013. In November 2019, Novartis has acquired The Medicines Company for USD 9.7 billion, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
The report provides insights into:
A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
Elaborated details on regulatory milestones and other development activities have been provided in this report.
The report also highlights the drug research and development activity details across the United States, Europe and Japan.
The report also covers the patents information with expiry timeline around Inclisiran.
The report contains forecasted sales for Inclisiran till 2030.
Comprehensive coverage of the late-stage emerging therapies (Phase III) for Duchenne Muscular Dystrophy.
The report also features the SWOT analysis with analyst insights and key findings of Inclisiran.
In the coming years, the market scenario for Duchenne Muscular Dystrophy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence Inclisiran dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Other emerging products for Duchenne Muscular Dystrophy are giving market competition to Inclisiran and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of Inclisiran.
Our in-depth analysis of the forecasted sales data of Inclisiran from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Inclisiran.
Key Questions Answered
Which company is developing Inclisiran along with the phase of the clinical study?
Which technology utilized in the development of Inclisiran?
What is the product type, route of administration and mechanism of action of Inclisiran?
What is the clinical trial status of the study and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Inclisiran development?
What are the key designations that have been granted to Inclisiran?
What is the forecasted market scenario of Inclisiran?
What is the history of Inclisiran and what is its future?
What is the forecasted sales of Inclisiran in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
What are the other emerging products available and how these are giving competition to Inclisiran?
Which are the late-stage emerging therapies under development for the treatment of the Duchenne Muscular Dystrophy?
Key Topics Covered
1. Drug Overview 1.1. Product Detail 1.2. Mechanism of Action 1.3. Dosage and Administration 1.4. Research and Development Activity 1.4.1. Clinical Development 1.4.2. Safety and Efficacy 1.5. Other Development Activities
2. Market Assesment 2.1. 7MM Market Analysis 2.2. The United States Market 2.3. Germany Market 2.4. France Market 2.5. Italy Market 2.6. Spain Market 2.7. United Kingdom Market 2.8. Japan Market
3. SWOT Analysis
4. Analyst Views
5. Market Competitors
6. Other Emerging Therapies
List of Tables Table 1 Inclisiran, Description Table 2 Inclisiran, Clinical Trial Description Table 3 Inclisiran, 7MM Market Size from 2020 to 2030 (in Million USD) Table 4 Market Competitors Table 5 Other Emerging Therapies
List of Figures Figure 1 The Development Timeline of INCLISIRAN Figure 2 Patent Details, INCLISIRAN Figure 3 Inclisiran, 7MM Market Size from 2020 to 2030 (in Million USD) Figure 4 Inclisiran, US Market Size from 2020 to 2030 (in Millions USD) Figure 5 Inclisiran, EU5 Market Size from 2020 to 2030 (in Millions USD) Figure 6 Inclisiran, Japan Market Size from 2020 to 2030 (in Millions USD)